NCT03790631View on ClinicalTrials.gov

The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring

CompletedOBSERVATIONAL
Enrollment

771

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Beta-lactam AntibioticsTherapeutic Drug MonitoringToxicityEfficacyImipenemMeropenemPiperacillinFlucloxacillinAmoxicillinCeftazidimeCefepime
Interventions
OTHER

The study is observational.

The study is observational.

Trial Locations (1)

1205

Geneva University Hospitals, Geneva

All Listed Sponsors
collaborator

University Hospital, Geneva

OTHER

lead

University of Geneva, Switzerland

OTHER

NCT03790631 - The OPTIMAL TDM Study: Determining Optimal Beta-lactam Plasma Concentrations Through Therapeutic Drug Monitoring | Biotech Hunter | Biotech Hunter